Skip to main content

Table 3 Response to nivolumab in 24 patients with measurable disease according to the potential predictive biomarkers

From: Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial

 

Objective response rate (n, %)

Disease control rate (n, %)

Baseline blood NLR

  > 2.9 (n = 14)

1 (7.1)

5 (35.7)

  ≤ 2.9 (n = 10)

3 (30)

6 (60.0)

Baseline serum Na

  < 135 mmol/L (n = 4)

0 (0.0)

1 (25.0)

  ≥ 135 mmol/L (n = 20)

4 (20.0)

10 (50.0)

Tumor PD-L1

 CPS < 1% (n = 10)

1 (10.0)

2 (20.0)

 CPS ≥ 1% (n = 8)

3 (37.5)

7 (87.5)

 CPS ≥ 10% (n = 2)

1 (50.0)

2 (100.0)

Tumor EBV

 Negative (n = 13)

3 (23.1)

6 (46.2)

 Positive (n = 5)

1 (20.0)

3 (60.0)

Tumor mutation burden

  ≤ 8.2/Mb (n = 6)

1 (16.7)

3 (50.0)

  > 8.2/Mb (n = 6)

2 (33.3)

3 (50.0)

  1. NLR Neutrophil–lymphocyte ratio, EBV Epstein-Barr Virus